AR091413A1 - Formulacion de anticuerpos - Google Patents
Formulacion de anticuerposInfo
- Publication number
- AR091413A1 AR091413A1 ARP130102057A AR091413A1 AR 091413 A1 AR091413 A1 AR 091413A1 AR P130102057 A ARP130102057 A AR P130102057A AR 091413 A1 AR091413 A1 AR 091413A1
- Authority
- AR
- Argentina
- Prior art keywords
- aqueous composition
- antibody
- composition according
- delivery device
- filled syringe
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Los anticuerpos anti-BAFFR se formulan como formulación líquida que comprende una alta concentración del ingrediente activo de anticuerpo para la entrega en un paciente sin altos niveles de agregación de anticuerpos. La composición farmacéutica acuosa puede incluir uno o más azúcares, un agente amortiguador, un surfactante, y/o un aminoácido libre. Reivindicación 2: La composición acuosa de la reivindicación 1 que tiene un pH de 5.5 - 6.5 y que comprende (i) un anticuerpo anti-BAFFR en el que el anticuerpo tiene una concentración de 18 a -165 mg/ml, y en el que dicho anticuerpo anti-BAFFR incluye CDR1, CDR2 y CDR3 de cadena pesada de SEC ID Nº 3, 4 y 5, respectivamente, y CDR1, CDR2 y CDR3 de cadena ligera de SEC ID Nº 6, 7 y 8, (ii) sacarosa, trehalosa o manitol como un estabilizador, (iii) histidina, citrato o succinato como un agente amortiguador, (iv) polisorbato 20, poloxámero 188 o hidroxipropil-b-ciclodextrina como un surfactante, y, opcionalmente, (v) arginina como un aminoácido. Reivindicación 25: Un dispositivo de suministro que comprende la composición acuosa de acuerdo con una cualquiera de las reivindicaciones 1 - 24. Reivindicación 26: Un jeringa pre-cargada que comprende la composición acuosa de acuerdo con una cualquiera de las reivindicaciones 1 - 24. Reivindicación 30: La composición acuosa según una cualquiera de las reivindicaciones 1 - 24, o el dispositivo de administración de la reivindicación 25, o la jeringa pre-cargada de la reivindicación 26, para su utilizar en el tratamiento de un neoplasma de células B, tal como linfoma, leucemia o mieloma. Reivindicación 31: La composición acuosa según una cualquiera de las reivindicaciones 1 - 24, o el dispositivo de administración de la reivindicación 25, o la jeringa pre-cargada de la reivindicación 26, para su utilizar en el tratamiento de artritis reumatoide, lupus eritematoso sistémico, síndrome de Sjögren, o pénfigo vulgar.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261658472P | 2012-06-12 | 2012-06-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR091413A1 true AR091413A1 (es) | 2015-02-04 |
Family
ID=48914378
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP130102057 AR091413A1 (es) | 2012-06-12 | 2013-06-12 | Formulacion de anticuerpos |
Country Status (36)
Country | Link |
---|---|
US (4) | US9216219B2 (es) |
EP (2) | EP2858671B1 (es) |
JP (1) | JP6265978B2 (es) |
KR (1) | KR102124820B1 (es) |
CN (1) | CN104363920B (es) |
AR (1) | AR091413A1 (es) |
AU (1) | AU2013276112B2 (es) |
BR (1) | BR112014030820B1 (es) |
CA (1) | CA2875386C (es) |
CL (1) | CL2014003370A1 (es) |
CO (1) | CO7151487A2 (es) |
CY (1) | CY1122181T1 (es) |
DK (1) | DK2858671T3 (es) |
EA (1) | EA033373B1 (es) |
EC (1) | ECSP15017314A (es) |
ES (1) | ES2751659T3 (es) |
GT (1) | GT201400285A (es) |
HK (1) | HK1203146A1 (es) |
HR (1) | HRP20191827T1 (es) |
HU (1) | HUE045523T2 (es) |
IL (1) | IL235966B (es) |
LT (1) | LT2858671T (es) |
MA (1) | MA37616A1 (es) |
MX (1) | MX363380B (es) |
MY (1) | MY179818A (es) |
NZ (1) | NZ630885A (es) |
PE (1) | PE20150200A1 (es) |
PH (1) | PH12014502778A1 (es) |
PL (1) | PL2858671T3 (es) |
PT (1) | PT2858671T (es) |
SG (1) | SG11201408174UA (es) |
SI (1) | SI2858671T1 (es) |
TN (1) | TN2014000488A1 (es) |
TW (1) | TWI653983B (es) |
WO (1) | WO2013186700A1 (es) |
ZA (1) | ZA201408547B (es) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT3459564T (pt) | 2010-01-06 | 2022-01-31 | Takeda Pharmaceuticals Co | Proteínas de ligação à calicreína plasmática |
US9458240B2 (en) * | 2010-12-10 | 2016-10-04 | Novartis Pharma Ag | Anti-BAFFR antibody formulations |
KR102107695B1 (ko) | 2011-01-06 | 2020-05-07 | 다이액스 코포레이션 | 혈장 칼리크레인 결합 단백질 |
US9216219B2 (en) | 2012-06-12 | 2015-12-22 | Novartis Ag | Anti-BAFFR antibody formulation |
TW201922795A (zh) | 2012-09-10 | 2019-06-16 | 愛爾蘭商尼歐托普生物科學公司 | 抗mcam抗體及相關使用方法 |
WO2014152232A2 (en) | 2013-03-15 | 2014-09-25 | Dyax Corp. | Anti-plasma kallikrein antibodies |
US10513555B2 (en) * | 2013-07-04 | 2019-12-24 | Prothena Biosciences Limited | Antibody formulations and methods |
CN104730237A (zh) * | 2013-12-23 | 2015-06-24 | 国家纳米科学中心 | 试纸及其应用以及检测甲胎蛋白抗原、乙肝表面抗原或HIV的gp41抗体的方法 |
WO2015136472A1 (en) | 2014-03-12 | 2015-09-17 | Prothena Biosciences Limited | Anti-laminin4 antibodies specific for lg4-5 |
US10407506B2 (en) | 2014-03-12 | 2019-09-10 | Prothena Biosciences Limited | Anti-MCAM antibodies and associated methods of use |
KR101597037B1 (ko) | 2014-06-26 | 2016-02-24 | 엘지디스플레이 주식회사 | 구동소자의 전기적 특성 편차를 보상할 수 있는 유기발광 표시장치 |
US10464999B2 (en) | 2015-01-28 | 2019-11-05 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
EP3286226A4 (en) * | 2015-03-30 | 2018-12-05 | Dyax Corp. | Plasma kallikrein inhibitors and uses thereof for preventing hereditary angioedema attack |
WO2017046776A2 (en) * | 2015-09-16 | 2017-03-23 | Prothena Biosciences Limited | Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis |
DK3386541T3 (da) * | 2015-12-07 | 2020-09-28 | Merck Patent Gmbh | Vandig farmaceutisk formulering omfattende anti-pd-1-antistof avelumab |
US11286307B2 (en) | 2015-12-11 | 2022-03-29 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack |
TWI836745B (zh) * | 2015-12-18 | 2024-03-21 | 美商上游生物公司 | 含有抗人類tslp受體抗體之醫藥組成物 |
MA45381A (fr) * | 2016-06-16 | 2021-04-21 | Janssen Vaccines & Prevention Bv | Formulation de vaccin contre le vih |
US20180118811A1 (en) | 2016-10-19 | 2018-05-03 | Invenra Inc. | Antibody constructs |
CN110291107B (zh) | 2016-12-22 | 2023-05-05 | 卡坦扎罗麦格纳格拉西亚大学 | 靶向cd43的独特唾液酸糖基化的癌症相关表位的单克隆抗体 |
CA3235178A1 (en) * | 2017-03-01 | 2018-09-07 | Medimmmune Limited | Formulations of monoclonal antibodies |
US11639391B2 (en) * | 2017-04-18 | 2023-05-02 | Dr. Reddy's Laboratories Limited | Stable liquid pharmaceutical composition |
DK3658184T3 (da) | 2017-07-27 | 2023-11-27 | Alexion Pharma Inc | Højkoncentrerede anti-c5-antistofformuleringer |
AU2018321335A1 (en) * | 2017-08-22 | 2020-02-27 | Biogen Ma Inc. | Pharmaceutical compositions containing anti-beta amyloid antibodies |
CA3083356A1 (en) * | 2017-11-29 | 2019-06-06 | Prothena Biosciences Limited | Lyophilized formulation of a monoclonal antibody against transthyretin |
SG11202011984UA (en) | 2018-06-05 | 2020-12-30 | King S College London | Btnl3/8 targeting constructs for delivery of payloads to the gastrointestinal system |
EP3897714A1 (en) * | 2018-12-18 | 2021-10-27 | Novartis AG | Protein solution formulation containing high concentration of an anti-vegf antibody |
PE20212185A1 (es) | 2019-02-18 | 2021-11-11 | Lilly Co Eli | Formulacion de anticuerpos terapeuticos |
TWI764097B (zh) * | 2019-02-26 | 2022-05-11 | 大陸商信達生物製藥(蘇州)有限公司 | 包含抗cd47抗體的製劑及其製備方法和用途 |
CA3160207A1 (en) | 2019-11-06 | 2021-05-14 | Novartis Ag | Treatment for sjogren's syndrome |
CN113116812A (zh) * | 2019-12-30 | 2021-07-16 | 百奥泰生物制药股份有限公司 | 含抗Trop2抗体-药物偶联物的制剂及其制备方法和应用 |
EP4094777A4 (en) * | 2020-01-21 | 2024-01-24 | Innovent Biologics (Suzhou) Co., Ltd. | RECOMBINANT FULLY HUMAN MONOCLONAL ANTI-TIGITE ANTIBODIES, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF |
IL300086A (en) | 2020-08-04 | 2023-03-01 | Novartis Ag | Treatment of B-cell malignancies |
CN115073598B (zh) * | 2021-03-15 | 2024-02-20 | 盛禾(中国)生物制药有限公司 | 一种抗baffr抗体及其应用 |
JP2024517796A (ja) | 2021-05-04 | 2024-04-23 | ノバルティス アーゲー | 抗baffr抗体を使用するループス腎炎の治療 |
CA3215919A1 (en) | 2021-05-04 | 2022-11-10 | Novartis Ag | Treatment for systemic lupus erythematosus using anti-baffr antibodies |
AU2022354054A1 (en) * | 2021-09-29 | 2024-03-28 | Dragonfly Therapeutics, Inc. | Antibodies targeting baff-r and use thereof |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
WO1990006952A1 (en) | 1988-12-22 | 1990-06-28 | Kirin-Amgen, Inc. | Chemically modified granulocyte colony stimulating factor |
US20020077461A1 (en) | 1996-04-24 | 2002-06-20 | Soren Bjorn | Pharmaceutical formulation |
US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
DE69942021D1 (de) | 1998-04-20 | 2010-04-01 | Glycart Biotechnology Ag | Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität |
EP2270150B2 (en) | 1999-04-09 | 2019-08-07 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
EP1192243A4 (en) | 1999-06-23 | 2003-05-28 | Univ Oregon Health & Science | METHOD FOR REINFORCING HEMATOPOIESE |
CA2412701A1 (en) | 2000-06-28 | 2002-01-03 | Glycofi, Inc. | Methods for producing modified glycoproteins |
WO2003035835A2 (en) | 2001-10-25 | 2003-05-01 | Genentech, Inc. | Glycoprotein compositions |
DK1441589T3 (da) | 2001-11-08 | 2012-08-06 | Abbott Biotherapeutics Corp | Stabil, flydende, farmaceutisk sammensætning af IgG-antistoffer |
EP1946776B1 (en) | 2002-02-27 | 2017-01-18 | Immunex Corporation | Stabilized tnfr-fc composition comprising arginine |
US20040191243A1 (en) | 2002-12-13 | 2004-09-30 | Bei Chen | System and method for stabilizing antibodies with histidine |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
EA200701211A1 (ru) * | 2004-12-31 | 2007-12-28 | Дженентек, Инк. | Полипептиды, которые связываются с br3, и их применение |
US8106163B2 (en) | 2008-07-17 | 2012-01-31 | Novartis Ag | Compositions and methods of use for therapeutic antibodies |
BR112012011539A8 (pt) * | 2009-11-17 | 2017-12-26 | Ipsen Pharma Sas | formulação para a combinação de hgh e rhigf-1 |
US9458240B2 (en) * | 2010-12-10 | 2016-10-04 | Novartis Pharma Ag | Anti-BAFFR antibody formulations |
WO2013083497A1 (en) | 2011-12-06 | 2013-06-13 | F. Hoffmann-La Roche Ag | Antibody formulation |
US9216219B2 (en) | 2012-06-12 | 2015-12-22 | Novartis Ag | Anti-BAFFR antibody formulation |
-
2013
- 2013-06-07 US US13/912,355 patent/US9216219B2/en active Active
- 2013-06-10 MA MA37616A patent/MA37616A1/fr unknown
- 2013-06-11 SI SI201331596T patent/SI2858671T1/sl unknown
- 2013-06-11 HU HUE13744818A patent/HUE045523T2/hu unknown
- 2013-06-11 DK DK13744818.9T patent/DK2858671T3/da active
- 2013-06-11 EP EP13744818.9A patent/EP2858671B1/en active Active
- 2013-06-11 BR BR112014030820-9A patent/BR112014030820B1/pt active IP Right Grant
- 2013-06-11 PL PL13744818T patent/PL2858671T3/pl unknown
- 2013-06-11 MX MX2014015262A patent/MX363380B/es unknown
- 2013-06-11 EA EA201492292A patent/EA033373B1/ru not_active IP Right Cessation
- 2013-06-11 KR KR1020157000336A patent/KR102124820B1/ko active IP Right Grant
- 2013-06-11 SG SG11201408174UA patent/SG11201408174UA/en unknown
- 2013-06-11 LT LT13744818T patent/LT2858671T/lt unknown
- 2013-06-11 AU AU2013276112A patent/AU2013276112B2/en active Active
- 2013-06-11 JP JP2015516723A patent/JP6265978B2/ja active Active
- 2013-06-11 NZ NZ630885A patent/NZ630885A/en not_active IP Right Cessation
- 2013-06-11 WO PCT/IB2013/054777 patent/WO2013186700A1/en active Application Filing
- 2013-06-11 ES ES13744818T patent/ES2751659T3/es active Active
- 2013-06-11 CN CN201380031181.8A patent/CN104363920B/zh active Active
- 2013-06-11 MY MYPI2014703690A patent/MY179818A/en unknown
- 2013-06-11 PT PT137448189T patent/PT2858671T/pt unknown
- 2013-06-11 CA CA2875386A patent/CA2875386C/en active Active
- 2013-06-11 TW TW102120795A patent/TWI653983B/zh active
- 2013-06-11 EP EP19185836.4A patent/EP3593814A1/en active Pending
- 2013-06-11 PE PE2014002437A patent/PE20150200A1/es not_active Application Discontinuation
- 2013-06-12 AR ARP130102057 patent/AR091413A1/es not_active Application Discontinuation
-
2014
- 2014-11-20 ZA ZA2014/08547A patent/ZA201408547B/en unknown
- 2014-11-21 TN TN2014000488A patent/TN2014000488A1/fr unknown
- 2014-11-27 IL IL235966A patent/IL235966B/en active IP Right Grant
- 2014-12-11 PH PH12014502778A patent/PH12014502778A1/en unknown
- 2014-12-11 CL CL2014003370A patent/CL2014003370A1/es unknown
- 2014-12-11 GT GT201400285A patent/GT201400285A/es unknown
- 2014-12-18 CO CO14278419A patent/CO7151487A2/es unknown
-
2015
- 2015-01-12 EC ECIEPI201517314A patent/ECSP15017314A/es unknown
- 2015-04-15 HK HK15103657.1A patent/HK1203146A1/xx unknown
- 2015-11-16 US US14/942,388 patent/US9751951B2/en active Active
-
2017
- 2017-08-31 US US15/692,490 patent/US20180051092A1/en not_active Abandoned
-
2018
- 2018-05-15 US US15/980,411 patent/US10689451B2/en active Active
-
2019
- 2019-10-09 HR HRP20191827TT patent/HRP20191827T1/hr unknown
- 2019-10-22 CY CY20191101096T patent/CY1122181T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR091413A1 (es) | Formulacion de anticuerpos | |
CO7111300A2 (es) | Formulación de anticuerpos | |
JP2015521593A5 (es) | ||
ECSP17034829A (es) | Formulación estable de proteina en solucion que contiene una alta concentracion de un anticuerpo anti-vegf | |
AR064826A1 (es) | Formulaciones de anticuerpos anti-il-13 y usos de los mismos. dispositivos, parche y jeringa | |
EA201492290A1 (ru) | Составы и способы для вагинальной доставки антипрогестинов | |
AR091530A1 (es) | Formulacion farmaceutica liquida de un anticuerpo y acetato | |
ECSP21043639A (es) | Formulación de solución de proteínas que contiene una alta concentración de un anticuerpo anti-vegf | |
MX2019014666A (es) | Composicion farmaceutica que comprende un conjugado de anticuerpo contra c-met-farmaco y uso del mismo. | |
PE20191550A1 (es) | COMPOSICION FARMACEUTICA ACUOSA DE ANTICUERPO MONOCLONAL ANTI-TNFalfa RECOMBINANTE | |
PE20160850A1 (es) | Sistema multiparticulado para administrar drogas | |
PE20171061A1 (es) | Composiciones farmaceuticas de accion prolongada para hepatitis c | |
AR102572A1 (es) | Formulación de solución de proteína estable que contiene alta concentración de un anticuerpo anti-vegf | |
PH12017501005A1 (en) | Injectable formulations of paracetamol | |
TH125691B (th) | สูตรของแอนดี้บอดี้ |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |